Market Place
Sourcing Support
BMS partner Zai Lab eyes China filing for KarXT after trial win
29 Oct 2024 //
FIERCE PHARMA
Zai Lab Reports Positive Data for KarXT in Schizophrenia
29 Oct 2024 //
BUSINESSWIRE
ZL-1310 Shows Promise In Small Cell Lung Cancer Patients
24 Oct 2024 //
BUSINESSWIRE
Zai Lab To Participate In November, December Investor Conferences
18 Oct 2024 //
BUSINESSWIRE
Zai Lab To Host Webcast On DLL3-Targeted ADC ZL-1310
17 Oct 2024 //
BUSINESSWIRE
Zai Lab To Announce Q3 2024 Financial Results On November 12
16 Oct 2024 //
BUSINESSWIRE
Zai Lab To Present ZL-1310 ADC Data At EORTC Symposium 2024
09 Oct 2024 //
BUSINESSWIRE
Zai Lab To Present Preclinical Data Of ZL-1503 For Atopic Dermatitis At EADV
17 Sep 2024 //
BUSINESSWIRE
Zai Lab To Present ZL-1218 Data At ESMO Congress 2024
27 Aug 2024 //
BUSINESSWIRE
Zai Lab Announces Participation in September Investor Conferences
22 Aug 2024 //
BUSINESSWIRE
Zai Lab Announces Second Quarter 2024 Financial Results and Corporate Updates
06 Aug 2024 //
BUSINESSWIRE
Argenx Reports H1 2024 Financials And Q2 Business Update
24 Jul 2024 //
GLOBENEWSWIRE
Zai Lab And Argenx Get China Approval For Efgartigimod In Myasthenia Gravis
16 Jul 2024 //
BUSINESSWIRE
Zai Lab Study In Cell Offers Insights On HRD-Positive Ovarian Cancer Treatment
15 Jul 2024 //
BUSINESSWIRE
Zai Lab To Announce Q2 2024 Results On August 6, 2024
10 Jul 2024 //
BUSINESSWIRE
Zai Lab: Reinhart Retiring, Amado New Global R&D Head
11 Jun 2024 //
BUSINESSWIRE
Zai Lab Initiates Global ZL-1102 Topical Psoriasis Phase 2
22 May 2024 //
BUSINESSWIRE
Zai Lab, Innoviva`s SUL-DUR Approved In China For Pneumonia
20 May 2024 //
BUSINESSWIRE
Zai Lab Announces Participation in May and June Investor Conferences
16 May 2024 //
BUSINESSWIRE
Zai Lab Gets China Priority Review For Efgartigimod CIDP Submission
14 May 2024 //
BUSINESSWIRE
BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC
13 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Zai Lab ROS1 NSCLC Drug AUGTYRO Approved In China
12 May 2024 //
BUSINESSWIRE
Zai Lab: Q1 2024 Financial Results, Corporate Updates
08 May 2024 //
BUSINESSWIRE
Zai Lab Q1 2024 Results, Updates On 5/8
15 Apr 2024 //
BUSINESSWIRE
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
11 Apr 2024 //
BUSINESSWIRE
Zai Lab Presentations at AACR 2024 Annual Meeting
02 Apr 2024 //
BUSINESSWIRE
Zai Lab Partner BMS Announces Trial KRAZATI (adagrasib) Meets Primary Endpoint
01 Apr 2024 //
BUSINESSWIRE
Zai Lab Partner Novocure Announces METIS Ph 3 Trial Met Primary Endpoint
27 Mar 2024 //
BUSINESSWIRE
Zai Lab to Present Data Highlighting ZL-1310
13 Mar 2024 //
BUSINESSWIRE
Zai Lab Announces Participation in March Investor Conference
06 Mar 2024 //
BUSINESSWIRE
Zai Lab to Present Final OS Data from Phase 3 NORA Study of ZEJULA
06 Mar 2024 //
BUSINESSWIRE
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
27 Feb 2024 //
BUSINESSWIRE
Zai Lab to Announce Full-Year 2023 Financial Results
25 Jan 2024 //
BUSINESSWIRE
Zai Lab Announces Participation in January Investor Conference
19 Dec 2023 //
BUSINESSWIRE
Zai Lab Announces the First Listing of VYVGART and Other Updates
12 Dec 2023 //
BUSINESSWIRE
NMPA grants breakthrough therapy designation to Zai Lab’s repotrectinib
31 Aug 2023 //
PHARMACEUTICAL TECHNOLOGY
Lynn Seely brings ex-Myovant colleague to Lyell`s C-suite; Nkarta, Zai Lab name new CFOs
07 Jul 2023 //
ENDPTS
argenx & Zai Lab Announce Approval of VYVGART® for Generalized Myasthenia Gravis
30 Jun 2023 //
GLOBENEWSWIRE
Zai Lab Announces NDA Acceptance of Repotrectinib for ROS1-positive NSCLC
28 Jun 2023 //
PRESS RELEASE
Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates
09 Nov 2022 //
PRESS RELEASE
Zai Lab to Present New Oncology Research at Society for Immunotherapy
08 Nov 2022 //
PRESS RELEASE
Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer
08 Nov 2022 //
PRESS RELEASE
Zai Lab (ZLAB) Stock: Why It Fell Over 22% Today
24 Oct 2022 //
PULSE2
Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022
18 Oct 2022 //
PRESS RELEASE
Seagen and Zai Lab ink partnership on Tivdak expansion into China
28 Sep 2022 //
ENDPTS
SEC Warns Chinese Companies About Risks of Auditor Changes
06 Sep 2022 //
WSJ
Zai`s Statement Regarding U.S./China Agreement Concerning PCAOB Inspection
26 Aug 2022 //
PRESS RELEASE
China and US consider possible solution for US-listed companies
25 Aug 2022 //
ENDPTS
Zai Lab Announces Participation in September Investor Conferences
23 Aug 2022 //
PRESS RELEASE
Zai Lab Announces Second Quarter 2022 Financial Results and Corporate Updates
09 Aug 2022 //
PRESS RELEASE
Why Earnings Season Could Be Great for Zai Lab (ZLAB)
08 Aug 2022 //
YAHOO
Zai Partner Karuna Announces Results from PIII EMERGENT-2 Trial of KarXT
08 Aug 2022 //
PRESS RELEASE
Zai Lab Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited
27 Jun 2022 //
PRESS RELEASE
Zai Lab Announces BTD Granted for Repotrectinib in China
10 Jun 2022 //
PRESS RELEASE
Investigation announced for Investors in Zai Lab over potential Wrongdoing
07 Jun 2022 //
OPENPR
Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study
03 Jun 2022 //
GLOBENEWSWIRE
Zai Lab’s Updated Statement on SEC Listing Matter
01 Jun 2022 //
PRESS RELEASE
Zai Lab to Present New PRIME Subgroup Analysis for Niraparib
31 May 2022 //
PRESS RELEASE
Zai Lab Announces Upcoming Presentations at June Investor Conferences
24 May 2022 //
PRESS RELEASE
